Introduction: There are several generic formulations of lamotrigine in Serbia that are widely used in the treatment of patients with epilepsy. The reduction of medical costs with use of generic formulations has potential risk because of the nature of disease, and it is necessary to investigate bioequivalence of each of generic formulations. Aim: Comparison of the efficacy of the reference and generic formulation of lamotrigine and theinvestigation of lamotrigine serum concentrations variation. Date were compared with in vitro results of dissolution profiles of the reference and generic tablet formulation. Patients (or Materials) and Methods: Lamotrigine steady-state concentrations were determined by high-performance liquid chromatography. In clinical study 16 patients participated, of whom 9 received reference formulation and 7 patients received generic formulation. Dissolution characteristics were evaluated at 3 points at physiologic pH range (pH 1.2, pH 4.5, pH 6.8), and difference (f1) and similarity (f2) tests were applied to dissolution data.
PP214-Tacrolimus Blood concenTraTion in PaTienTs suBjecTed To renal TransPlanTaTion: The influence of Gender
Results: Average TTC in outpatient examinations of male patients (7.098 [3.4870] ng/mL) were significantly higher (t = 2.432, P = 0.015) compared with female transplant recipients (6.852 [3.2726] ng/mL).In 25.3% of male examinations, TTC were within the "subtherapeutic" range (< 5 ng/mL), while 28.3% of female examinations were within the same range; the difference was statistically significant. On the other hand, the number of examinations in which the TTC were "over the therapeutic" range (> 10 ng/mL) in females were significantly lower than in males. Introduction: Pharmacokinetic data of GCV are limited in HSCT patients under preemptive therapy and its induced hematologic toxicity still problematic.The aim of this study was to evaluate the PK of GCV after single and multiple doses in HSCT patients with CMV infection and to identify correlation between PK parameters and hematologic toxicity. Patients (or Materials) and Methods: A PK study was conducted between October 2008 and December 2009 at MG hospital in Beirut, after IV GCV treatment in HSCT recipients with CMV infection. CMV disease was recognized by the combination of clinical signs and antigenemia. Patients received 1-hour infusion of 5 mg/kg q 12h for 14 days, and a complete PK study was performed at days 1, 7, and 14. A compartmental and no PK analysis were performed, and plasma GCV was analyzed by an HPLC validated method with UV detection. An ANOVA analysis associated to Freadman test was performed to compare the mean PK parameters. The 95% CI was calculated for some parameters and P < 0.05 was considered significant. Results: Twelve patients were enrolled in this study. A significant difference in creatinine clearance (Clcr) and trombecytopenia, 
Conclusion

